INTRODUCTION: Alzheimer's disease and related dementias (ADRD) are highly prevalent conditions, and prior efforts to develop predictive models have relied on demographic and clinical risk factors using traditional logistical regression methods. We hypothesized that machine-learning algorithms using administrative claims data may represent a novel approach to predicting ADRD.
RESEARCH IN CONTEXT
1. Systematic review: Previous attempts to predict incident dementia have relied on extensive clinical evaluations, cognitive testing, laboratory testing, neuroimaging, genetic factors, demographics, and lifestyle variables. Applying machine learning to a large administrative claims dataset to identify individuals at increased likelihood for near-term diagnosis of dementia had not been tested.
Interpretation:
A 50-variable model to identify those at risk for near-term diagnosis of dementia was created and validated. Based on AUC analysis, the model compared favorably with other historical attempts at modeling more traditional forms of data.
3. Future direction: Models, such as the one developed here, could be used to identify populations of higher prior probability for near-term diagnosis of dementia. These could then be subjected to more in-depth scrutiny for intervention or dementia-related research eligibility.
Identifying Incident Dementia by Applying Machine Learning to a very large Administrative Claims Dataset

INTRODUCTION
As many as 35.6 million people lived with dementia worldwide in 2010 and those numbers are expected to double every 20 years to 115.4 million by 2050 (1) . Within the United States, the annual number of incident cases is expected to more than double from 377,000 in 1995 to 959,000 yearly by 2050 (2) leading to a prevalence of 13.8 million (3) . The total health care and long-term care costs associated with dementia are expected to reach a historic high of over quarter of a trillion dollars in the US in 2018 (4) .
Tools are needed to assist clinicians, public health workers, and epidemiologists in identifying individuals at risk for dementia and addressing this unfolding epidemic.
Although the upward trend in incidence of Alzheimer's disease and the ravaging effects it has on the subject and caregivers is well documented, there has been very little published work building predictive models which help with identifying people with high risk prior to the onset of the disease. Barnes To that end, an effort was undertaken to develop and test a model which would predict incipient ADRD using machine learning and compare the performance of that model to previous models derived with traditional logistic regression techniques or based on individualized diagnostic testing.
METHODS
Data Set
This study utilizes data between 2001 and 2015 from the OptumLabs® Data Warehouse (OLDW), (9) which includes a national de-identified dataset of more than 125 million privately insured individuals that is geographically and racially diverse, Census Regions (10) . OLDW provides full access to professional, facility, and outpatient prescription medication claims. Patient-identifying information was encrypted or removed from the study database prior to its release to the study investigators, such that it is compliant with HIPAA and exempt from Institutional Review Board review.
Definition of Outcome
The study outcome was a binary variable indicating a new diagnosis ADRD. The identification rules for diagnosed ADRD cases were developed based on past work (11) , and extended in consultation with an Expert Advisory Panel consisting of clinicians and experts from academia. Individuals must have met at least one of the following criteria:
• a medical claim with ADRD diagnosis codes in any header position in an inpatient setting,
• a medical claim with an ADRD diagnosis code followed by another claim with an ADRD diagnosis code within 1 to 730 days; both claims can be in any setting, and the codes in any header position,
• a pharmacy claim for donepezil hydrochloride, galantamine hydrobromide, rivastigmine tartrate or tacrine hydrochloride, and
• a pharmacy claim for memantine hydrochloride along with a medical claim with an ADRD diagnosis code in any setting and any header position within 0 to 730 days. The confirmation with a diagnosis claim is required because memantine hydrochloride is also used as an augmentation therapy for anxiety disorders (OCD, ADHD, etc.) (12) as well as help slowing down the tolerance development to opioids (13) .
The index date for individuals (cases), whose diagnosis was confirmed using the above criteria, was set using the earliest occurrence of a medical claim with an ADRD diagnosis code in any setting or a pharmacy claim for any of the above drugs. To ensure that the identified individuals have incident rather than prevalent ADRD, we required a 60-month period of continuous enrollment without any of the above diagnosis or pharmacy claims before the index date. Figure 1 shows examples of how the index date and confirmation date are labeled in different situations with relevant inpatient, outpatient and pharmacy claims.
Training and Testing
The ADRD predictive model was trained and tested using a nested case-control study design (8) .
Step-wise demonstration of how the study population was assembled is depicted in Figure 2 . OLDW contains 59,748,354 unique individuals with any period of medical and pharmacy coverage between 1/1/2007 and 6/30/2015. The end date was chosen so that the entire study could be done using medical claims before ICD-10 diagnosis codes were required. The start date was chosen to limit the population to a size amenable for processing on the available hardware. The final cohort size (over 200,000 training observations and nearly 600,000 in test) indicated that an earlier start date was not needed to have sufficient data.
We excluded 51,471,280 individuals who did not have at least one timespan with more than 5 years of continuous enrollment. Also, 740,363 individuals who are in longterm care facilities (LTC) were excluded, because LTC residence is strongly associated with pre-existing dementia (14) and also because dementia in LTC settings may be under-coded, leading the claims based identification algorithms to mark them incorrectly as cases or controls [ (15), (16) ]. This resulted in 8,257,557 eligible individuals of whom 238,336 individuals had a diagnosis of ADRD based on the outcome definitions described above.
In that ADRD cohort, we excluded 41,845 individuals who did not have a confirmatory diagnosis. We also excluded 150,127 individuals who had less than 5 years of continuous enrollment immediately prior to the index date within the current enrollment span or who were less than 45 years old on the index date. To minimize bias from inclusion of individuals who had no encounters with the health care system, we excluded 1,419 people with no claims. These individuals may not be engaged in their health care management and would be poor participants in randomized controlled trials (RCT). Ultimately, there were 44,945 people in the incident ADRD cohort.
In order to minimize the risk of confounding based on duration of enrollment, the index dates for the controls cohort were selected to match the distribution of the case's enrollment duration (Prince et al., 2013) . Specifically, for each person in the case cohort, we computed the time from enrollment to the index date, and divided them in 
Independent Variables
For training and test cohorts, we collected claims for individuals for the fourth and fifth The diagnosis, drug and procedure codes were modeled using binary variables, with the value set to 1 if there was at least a single claim with a particular code. Age was modeled in ranges of 5 year increments from 40-44 to 85-89. Because of privacy concerns due to small numbers, ages greater than 89 years were mapped to 89 years.
Using this process, the training model matrix had 10,363 clinical, pharmaceutical, and demographic variables (all binary) and 215,196 rows.
Analytic Methods
We divided the analysis into two conceptual phases: a first phase that performs feature selection and a second phase that uses the best features to create a final model. In the first phase a Lasso logistic regression algorithm was run to identify the top 50 important predictors of the dependent variable. The Lasso algorithm outperforms other machine learning algorithms such as Random Forests and Regression Trees for variable selection (23) . Sensitivity tests were performed to show that using up to 500 variables did not demonstrably change the accuracy of the model. The 50-variable ADRD model (Table 3 ) was used to compute scores for each individual in the training and test datasets. Scores need to be converted into a threshold above which an action will be taken with the individual. A common method to choose the threshold is to set it so the fraction of scores above the threshold is equal to the case prevalence in the population. Using this method, the amount of outreach effort that would be expended toward intervening on a potentially "at risk" group is proportional to the prevalence. Scores which were at or above the threshold were classified as at-risk for ADRD, while scores which were below the threshold were classified as not at-risk. The sensitivity, specificity and lift of the model at this threshold for training and test populations were also computed. Lift is defined here as the positive predictive value of this model divided by the case prevalence. Thus if the lift is 10, then the model reaches 10 times as many true positives as a random outreach effort.
Because the prevalence and biological causes of dementia vary based on age, the classification into predicted outcome was repeated after stratifying the individual scores using three age ranges viz., 40-64, 65-74 and 75-89, and computing thresholds for each range based on the prevalence of cases in that range. The sensitivity, specificity and lift for each of the age ranges, as well as for an entire cohort using three thresholds were computed. of the controls have fewer than 3 codes (if a case or control has 3 codes, then there will be 3 ones in the row for that observation and rest zeros). This shows that three years prior to the index data, there are only a few codes in claims for majority of the members in the cohort. The data sparsity makes this a very hard binary classification problem as evidenced further in the results below.
RESULTS
Cohort Characteristics
Model Characteristics
The The dashed line indicates the threshold; all scores greater than or equal (lesser than) that line would be classified as cases (controls). These plots depict separation of the cases and controls at higher score range, with a large overlap in scores at the lower range. The top 5 pharmacy codes are psychoactive drugs.
DISCUSSION
A recent systematic review of dementia risk prediction models (27) As noted earlier, a national de-identified dataset was used to train and test the models. While the census region-level information for members in the cohort is available, it was not used to control for potential regional differences in the model for the following reasons. First is that while it may help with adjusting for access to care, it will not help with addressing differences in coding behavior between providers, difference in insurance plan types, etc. Second, we wanted the model to be usable in a variety of production settings with claims coming in from different sources without the need for that additional information. This dataset has a combination of so many benefit plans, regions, etc. potential bias in any one of them would not effect the overall model. This model becomes increasingly useful as potential disease-modifying treatments for dementia are developed to a stage for clinical testing. Thus, the ability to achieve a lift of 6.4 means that a patient identified by the model will be 6.4 times more likely to be diagnosed in the near-term with dementia. An identified cohort with such enhanced prior probability could be much more cost-effectively screened for clinical research than an unselected population.
A limitation of our study is that dementia may be undercoded, presenting a challenge for training models; in one study, Alzheimer's disease and related dementias was recorded as a diagnosis for less than 25% of patients with moderate to severe cognitive impairment (42) ; and in another, physicians were unaware of cognitive impairment in more than 40% of their cognitively impaired patients (43) . Among participants in a Medicare Alzheimer's Disease Demonstration, less than 20% of participants were classified with dementia of the Alzheimer type based on a year's worth of claims data, although 68% carried that diagnosis upon referral (44) . A review of seven studies examining the extent to which dementia is omitted as a cause of death, found that the reporting on death certificates ranged from a 7.2% to 41.8% (45) . 
